Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 137,273 shares, an increase of 310.9% from the June 15th total of 33,404 shares. Based on an average trading volume of 4,260,794 shares, the days-to-cover ratio is currently 0.0 days. Currently, 24.6% of the shares of the company are short sold.
Shuttle Pharmaceuticals Stock Up 1.4%
SHPH traded up $0.04 during midday trading on Monday, reaching $2.96. The company had a trading volume of 12,456,514 shares, compared to its average volume of 2,341,409. The business has a 50-day moving average of $4.86 and a two-hundred day moving average of $9.96. Shuttle Pharmaceuticals has a 1 year low of $2.71 and a 1 year high of $55.90. The company has a market cap of $1.89 million, a P/E ratio of -0.06 and a beta of 0.29.
Insiders Place Their Bets
In other news, major shareholder Financial Lp Hrt bought 25,836 shares of the company’s stock in a transaction on Monday, June 29th. The shares were acquired at an average cost of $3.44 per share, with a total value of $88,875.84. Following the completion of the transaction, the insider owned 71,842 shares of the company’s stock, valued at approximately $247,136.48. This trade represents a 56.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders bought 53,398 shares of company stock valued at $181,764 and sold 38,133 shares valued at $132,128. Corporate insiders own 12.60% of the company’s stock.
Institutional Investors Weigh In On Shuttle Pharmaceuticals
Analyst Upgrades and Downgrades
Several research firms have recently commented on SHPH. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Read Our Latest Research Report on Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
Featured Stories
- Five stocks we like better than Shuttle Pharmaceuticals
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
